Serum insulin-like growth factor-1 is not a useful marker of prostate cancer

BJU International

Volumn 83, Issue 9, 1999, Pages 996-999

  Cutting, C W M ^a   Hunt, C ^a   Nisbet, J A ^a   Bland, J M ^a   Dalgleish, A G ^b   Kirby, R S ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenocarcinoma; Insulin like growth factor 1; Prostate; Prostate specific antigen; Prostatic biopsies

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; BIOPSY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0000820311     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00088.x     Document Type: Article

References (28)

1. 1 Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Rev 1989; 10: 68-91
2. 2 Baserga R, Resnicoff M, D'Ambrosio C, Valentinis B. The role of the IGF-I receptor in apoptosis. Vitamins Hormones 1997; 53: 65-98
3. 3 Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-20
4. 4 Kaicer EK, Blat C, Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinomn cells. Growth Factors 1991; 4: 231-7
5. 5 Pietrzkowski Z, Mulholland G, Gomella L. Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res 1993; 53: 1102-6
6. 6 Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endoc Metab 1991; 73: 401-7
7. 7 Ritchie CK, Andrews LR, Thomas KG, Tindall DJ. Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138: 1145-50
8. 8 Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endoc Metab 1993; 76: 1031-5
9. 9 Kanety H. Madjar Y, Dagan Y et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endoc Metab 1993; 77: 229-33
10. 10 Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endoc 1997; 46: 333-42
11. 11 Mantzoros CS, Tzonou A, Siynorello LB, Stampfer M, Trichopoulos D, Adami HO, Insulin-like growth factor I in relation to prostate cancer and benign prostatie hyperplasia. Br J Cancer 1997; 76: 1115-8
12. 12 Chan JM, Stampfer MJ. Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6
13. 15 Zapf J, Schmid C, Froesch ER. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endoc Metab 1984; 13: 3-30
14. 14 Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-spocific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endoc Metab 1992; 75: 1046-53
15. 15 Juul A, Bang P, Hertel NT et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endoc Metab 1994; 78: 744-52
16. 16 Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endoc 1994; 41: 85-93
17. 17 Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997; 145: 970-6
18. 18 Unterman TG, Vazques RM, Slas AJ, Martyn PA, Phillips LS. Nutrition and somatomedin. XIII. Usefulness of somatomedin-C in nutritional assessment. Am J Med 1985; 78: 228-34
19. 19 Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrine Rev 1994; 15: 80-101
20. 20 Clemmons DR, Klibanski A, Underwood LE et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endoc Metab 1981; 53: 1247-50
21. 21 Landin-Wilhelmsen K, Wilhelmsen L. Lappas G et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endoc 1944; 41: 351-7
22. 22 Poehlman ET, Copeland KC. Influence of physical activity on insulin-like growth factor-I in healthy younger and older men. J Clin Endoc Metab 1990; 71: 1468-73
23. 23 Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterol 1986; 91: 830-6
24. 24 Lecornu M, David L, Francois R. Low serum somatomedin activity in celiac disease. A misleading aspect in growth failure from asymptomatic celiac disease. Helvetica Paediatrica Acta 1978; 33: 509-16
25. 25 Counts DR, Gwirtsman H, Carlsson LM, Lesein M, Cutler GB Jr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endoc Metab 1992; 75: 762-7
26. 26 Wu JC, Daughaday WH, Lee SD et al. Radioimmunonssay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988; 112: 589-94
27. 27 Maes M, Underwood LE, Ketelslegers JM, Low serum somatomedin-C in insulin-dependent diabetes: evidence for a postreceptor mechanism. Endocrinology 1986; 118: 377-82
28. 28 Clemmons DR, Underwood LE. Somatomedin-C/insulin-like growth factor I in acromegaly. Clin Endoc Metab 1986; 15: 629-53